XENE
Xenon Pharmaceuticals Inc.
$37.35
+$0.40(+1.08%)
18
Overall
--
Value
18
Tech
--
Quality
Market Cap
$2.75B
Volume
867.58K
52W Range
$26.74 - $46.00
Target Price
$54.82
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $15.6M | $1.8M | $311.0K | -- | $6.8M | $32.2M | $18.4M | $9.4M | -- | -- | ||
| Total Revenue | $15.6M | $1.8M | $311.0K | -- | $6.8M | $32.2M | $18.4M | $9.4M | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $15.6M | $1.8M | $311.0K | -- | $6.8M | $32.2M | $18.4M | $9.4M | -- | -- | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $24.9M | $26.6M | $32.9M | $38.0M | $49.6M | $63.5M | $97.4M | $138.6M | $214.1M | $279.3M | ||
| Research & Development | $15.2M | $19.8M | $25.6M | $23.6M | $38.8M | $50.5M | $75.5M | $105.8M | $167.5M | $210.4M | ||
| Research Expense | $15.2M | $19.8M | $25.6M | $23.6M | $38.8M | $50.5M | $75.5M | $105.8M | $167.5M | $210.4M | ||
| Selling, General & Administrative | $9.8M | $6.8M | $7.3M | $8.4M | $10.8M | $12.9M | $22.0M | $32.8M | $46.5M | $68.9M | ||
| General & Administrative Expenses | $9.8M | $6.8M | $7.3M | $8.4M | $10.8M | $12.9M | $22.0M | $32.8M | $46.5M | $68.9M | ||
| Salaries & Wages | -- | -- | -- | -- | -- | -- | -- | $20.4M | $32.4M | $50.7M | ||
| Amortization | -- | -- | $-11.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | $6.0M | $-436.0K | $536.0K | $591.0K | $1.1M | $1.6M | $1.6M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-9.4M | $-24.8M | $-32.6M | $-38.0M | $-42.8M | $-31.3M | $-79.0M | $-129.1M | $-214.1M | $-279.3M | ||
| EBITDA | $-14.7M | $-22.1M | $-30.0M | $-32.3M | $-39.2M | $-28.0M | $-78.1M | $-123.6M | $-179.4M | $-234.6M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | $1.4M | $1.4M | $484.0K | -- | -- | -- | -- | ||
| Intinc | $542.0K | $504.0K | $477.0K | $1.2M | $2.4M | $2.3M | $466.0K | $8.7M | $27.6M | $41.9M | ||
| Net Non-Operating Interest Income/Expense | $542.0K | $504.0K | $477.0K | $-178.0K | $919.0K | $1.8M | $466.0K | $8.7M | $27.6M | $41.9M | ||
| Other Income/Expense | -- | -- | -- | $-4.4M | -- | $984.0K | $719.0K | $-4.8M | $-3.5M | -- | ||
| Other Special Charges | -- | -- | -- | $4.4M | -- | $-988.0K | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-15.8M | $-23.0M | $-30.7M | $-33.1M | $-40.2M | $-28.6M | $-79.0M | $-125.3M | $-182.7M | $-238.4M | ||
| Pre-Tax Income | $-15.8M | $-23.0M | $-30.7M | $-34.5M | $-41.6M | $-29.1M | $-78.9M | $-125.3M | $-182.7M | $-238.4M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $995.0K | $72.0K | $-350.0K | $-24.0K | $-23.0K | $-257.0K | $-6.0K | $118.0K | $-292.0K | $-4.1M | ||
| NET INCOME | ||||||||||||
| Net Income | $-15.8M | $-23.0M | $-30.7M | $-34.5M | $-41.6M | $-28.8M | $-78.9M | $-125.4M | $-182.4M | $-234.3M | ||
| Net Income (Continuing Operations) | $-15.8M | $-23.0M | $-30.7M | $-34.5M | $-41.6M | $-28.8M | $-78.9M | $-125.4M | $-182.4M | $-234.3M | ||
| Net Income (Discontinued Operations) | $-15.8M | $-23.0M | $-30.7M | $-34.5M | $-41.6M | $-28.8M | $-78.9M | $-125.4M | $-182.4M | $-234.3M | ||
| Net Income (Common Stockholders) | $-15.8M | $-23.0M | $-30.7M | $-31.6M | $-40.0M | $-28.0M | $-77.1M | $-124.9M | $-182.4M | $-234.3M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-242.5M | ||
| TOTALS | ||||||||||||
| Total Expenses | $24.9M | $26.6M | $32.9M | $38.0M | $49.6M | $63.5M | $97.4M | $138.6M | $214.1M | $279.3M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $14.3M | $15.5M | $18.0M | $19.4M | $25.9M | $34.5M | $43.6M | $60.5M | $66.9M | $77.9M | ||
| Average Shares Outstanding (Diluted) | $14.3M | $15.5M | $18.0M | $21.2M | $25.9M | $34.5M | $43.6M | $60.5M | $66.9M | $77.9M | ||
| Shares Outstanding | $14.4M | $17.9M | $18.0M | $25.8M | $35.0M | $35.8M | $51.9M | $63.0M | $75.4M | $76.5M | ||
| Basic EPS | $-1.1 | $-1.48 | $-1.71 | $-1.63 | $-1.54 | $-0.81 | $-1.77 | $-2.06 | $-2.73 | $-3.01 | ||
| Basic EPS (Continuing Operations) | $-1.1 | $-1.48 | $-1.71 | $-1.63 | $-1.54 | $-0.81 | $-1.77 | $-2.06 | $-2.73 | $-3.01 | ||
| Diluted EPS | $-1.1 | $-1.48 | $-1.72 | $-1.63 | $-1.54 | $-0.81 | $-1.77 | $-2.06 | $-2.73 | $-3.01 | ||
| Diluted EPS (Continuing Operations) | $-1.1 | $-1.48 | $-1.72 | -- | -- | -- | -- | $-2.06 | $-2.73 | $-3.01 | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | -- | -- | -- | $-2.9M | $-1.6M | $824.0K | $1.8M | -- | -- | -- | ||
| Other Gand A | $9.8M | $6.8M | $7.3M | $8.4M | $10.8M | $12.9M | $22.0M | $32.8M | $46.5M | $68.9M | ||
| Otherunder Preferred Stock Dividend | -- | -- | -- | $-2.9M | $-1.6M | $824.0K | $1.8M | -- | -- | -- | ||
| Preferred Stock Dividends | -- | -- | -- | $-2.9M | $-1.6M | $824.0K | $1.8M | -- | -- | -- | ||
| Rent And Landing Fees | $-917.0K | $-936.0K | $-1.1M | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | XENE | $37.35 | +1.1% | 867.58K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Xenon Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW